Skip to main content
. Author manuscript; available in PMC: 2014 Apr 11.
Published in final edited form as: J Med Chem. 2013 Mar 25;56(7):2747–2763. doi: 10.1021/jm301253y

Figure 3.

Figure 3

Melanocortin receptor pharmacologically of the control NDP-MSH peptide and analogues 6–11 that were modified at the DPhe position. Agonist profiles at the mMC1R and mMC3-5Rs are shown in the top four panels. The mMC3R antagonist profiles for molecules 9 and 11 are shown in the bottom two panels. Both ligands 9 and 11 also possess partial mMC3R agonist activity at the higher concentrations examined.